treated with an NACT approach ( supplemental eTable 3 ), including all of the intravenous regimens recommended for conventional treatment of stage II–IV disease (ie, PDS followed by chemotherapy). Bevacizumab-Containing Regimens for Patients Treated With
Search Results
NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019
Featured Updates to the NCCN Guidelines
Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum-Gamez, Lisa Barroilhet, Kian Behbakht, Andrew Berchuck, Jonathan S. Berek, Lee-may Chen, Mihaela Cristea, Marie DeRosa, Adam C. ElNaggar, David M. Gershenson, Heidi J. Gray, Ardeshir Hakam, Angela Jain, Carolyn Johnston, Charles A. Leath III, Joyce Liu, Haider Mahdi, Daniela Matei, Michael McHale, Karen McLean, David M. O’Malley, Richard T. Penson, Sanja Percac-Lima, Elena Ratner, Steven W. Remmenga, Paul Sabbatini, Theresa L. Werner, Emese Zsiros, Jennifer L. Burns, and Anita M. Engh
Complete Response to Erlotinib and Bevacizumab in a Patient With Biphenotypic (Hepatobiliary) Primary Liver Carcinoma
Amy Zhou, Manik Amin, Kathryn J. Fowler, Elizabeth M. Brunt, Jesse Keller, and Benjamin Tan
, but prompted consideration for treatment with an EGFR inhibitor. She was subsequently started on erlotinib, an anti-EGFR small tyrosine kinase inhibitor, at 150 mg orally daily and bevacizumab at 15 mg/kg intravenously every 3 weeks. She tolerated
Optimal First-Line and Maintenance Treatments for Advanced-Stage Nonsquamous Non-Small Cell Lung Cancer
Ryan D. Gentzler and Jyoti D. Patel
, visit NCCN.org ). 2 Histology has also become particularly relevant for treatment decisions, and patients with squamous histology NSCLC are not eligible for treatment with pemetrexed or bevacizumab, 2 key drugs that will be discussed in detail. For
Central Nervous System Cancers
Steven S. Brem, Philip J. Bierman, Henry Brem, Nicholas Butowski, Marc C. Chamberlain, Ennio A. Chiocca, Lisa M. DeAngelis, Robert A. Fenstermaker, Allan Friedman, Mark R. Gilbert, Deneen Hesser, Larry Junck, Gerald P. Linette, Jay S. Loeffler, Moshe H. Maor, Madison Michael, Paul L. Moots, Tara Morrison, Maciej Mrugala, Louis Burt Nabors, Herbert B. Newton, Jana Portnow, Jeffrey J. Raizer, Lawrence Recht, Dennis C. Shrieve, Allen K. Sills Jr, Frank D. Vrionis, and Patrick Y. Wen
-line or salvage chemotherapy include combination PCV, 40 cyclophosphamide, 41 and platinum-based regimens. 42 Anaplastic gliomas may also be treated by irinotecan 43 or etoposide. 44 Bevacizumab, an antiangiogenic agent, received accelerated approval
Treatment Trends and Clinical Outcomes of Left-Sided RAS/RAF Wild-Type Metastatic Colorectal Cancer in the United States
Christopher Nevala-Plagemann, Siddharth Iyengar, Andrew D. Trunk, Lisa Pappas, Benjamin Haaland, and Ignacio Garrido-Laguna
patients who develop or present with metastatic CRC (mCRC) remain poor. Several targeted therapies have been approved by the FDA for use in the management of RAS/RAF wild-type (WT) mCRC. These agents include bevacizumab, a monoclonal antibody targeting
Colon Cancer
Al B. Benson III, J. Pablo Arnoletti, Tanios Bekaii-Saab, Emily Chan, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Raza A. Dilawari, Paul F. Engstrom, Peter C. Enzinger, James W. Fleshman Jr., Charles S. Fuchs, Jean L. Grem, James A. Knol, Lucille A. Leong, Edward Lin, Kilian Salerno May, Mary F. Mulcahy, Kate Murphy, Eric Rohren, David P. Ryan, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, William Small Jr., Constantinos T. Sofocleous, Alan P. Venook, and Christopher Willett
bevacizumab, cetuximab, panitumumab, or irinotecan in adjuvant therapy for nonmetastatic disease outside the setting of a clinical trial. Adenocarcinomas of the small bowel or appendix, for which no NCCN Guidelines exist, may be treated with systemic
NCCN Guidelines Updates: New Immunotherapy Strategies for Improving Outcomes in Non–Small Cell Lung Cancer
Matthew A. Gubens and Marianne Davies
and squamous cell carcinoma (SCC), as the panel’s preferred first-line option (category 1) when PD-L1 expression is ≥50%. Chemotherapy + pembrolizumab (or atezolizumab + bevacizumab) is also a category 1 recommendation suitable for select patients with
Metastatic Mucinous Ovarian Cancer and Treatment Decisions Based on Histology and Molecular Markers Rather Than the Primary Location
Angela Jain, Paula D. Ryan, and Michael V. Seiden
oxaliplatin (FOLFOX) with bevacizumab. Before the start of treatment, evaluation of tumor markers was notable for a carcinoembryonic antigen (CEA), alfa-feto-protein (AFP), and CA-125 levels of 644, 5149, and 16, respectively. After 6 treatments, CEA levels
Evaluation of Scores to Reflect Toxicity Impact on Quality of Life of Patients With Platinum-Resistant Ovarian Cancer: AURELIA Substudy
Justine Lequesne, Florence Joly, Julien Peron, Isabelle Ray-Coquard, Anne-Claire Hardy-Bessard, Frédéric Selle, Dominique Berton, Philippe Follana, Michel Fabbro, Alain Lortholary, Eric Pujade-Lauraine, Sophie Lefèvre-Arbogast, and Elodie Coquan
-label phase III trial designed to assess the efficacy of bevacizumab in addition to palliative chemotherapy for patients with PROC. 11 Methods Data Source In the AURELIA study, 361 patients were randomly assigned to receive chemotherapy either
Optimizing Adjuvant Therapy for Localized Colon Cancer and Treatment Selection in Advanced Colorectal Cancer
Axel Grothey and Alan P. Venook
or without bevacizumab. This is based on the results of the TRIBE study that showed FOLOXIRI/bevacizumab produced a 4-month advantage in overall survival (OS) versus FOLFIRI/bevacizumab ( P =.03). 3 , 4 “It doesn't, however, increase your ability to
